Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
47.46
USD
|
+4.35%
|
|
+7.67%
|
+113.02%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,105
|
883.5
|
112.1
|
190.9
|
811.9
|
-
|
-
|
Enterprise Value (EV)
1 |
2,105
|
883.5
|
112.1
|
109.6
|
406.3
|
499.2
|
811.9
|
P/E ratio
|
-29.9
x
|
-5
x
|
-0.51
x
|
-1.19
x
|
-4.72
x
|
-4.75
x
|
-6.35
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
78
x
|
359
x
|
822
x
|
9.81
x
|
EV / Revenue
|
-
|
-
|
-
|
44.8
x
|
180
x
|
506
x
|
9.81
x
|
EV / EBITDA
|
-34
x
|
-5.29
x
|
-0.52
x
|
-0.87
x
|
-2.36
x
|
-2.67
x
|
-3.73
x
|
EV / FCF
|
-40
x
|
-7.03
x
|
-
|
-0.99
x
|
-3.68
x
|
-3.36
x
|
-9.9
x
|
FCF Yield
|
-2.5%
|
-14.2%
|
-
|
-101%
|
-27.2%
|
-29.7%
|
-10.1%
|
Price to Book
|
-
|
-
|
-
|
2.81
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
2,550
|
2,990
|
3,141
|
8,570
|
17,108
|
-
|
-
|
Reference price
2 |
825.3
|
295.5
|
35.70
|
22.28
|
47.46
|
47.46
|
47.46
|
Announcement Date
|
3/17/21
|
2/28/22
|
2/7/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
2.447
|
2.261
|
0.9873
|
82.8
|
EBITDA
1 |
-61.92
|
-167.2
|
-214.6
|
-125.9
|
-172.2
|
-186.9
|
-217.9
|
EBIT
1 |
-61.97
|
-167.3
|
-215
|
-126.4
|
-160.9
|
-172.8
|
-122.8
|
Operating Margin
|
-
|
-
|
-
|
-5,164.41%
|
-7,117.03%
|
-17,497.09%
|
-148.34%
|
Earnings before Tax (EBT)
1 |
-61.83
|
-167.1
|
-214
|
-123.3
|
-156.1
|
-178.6
|
-149.3
|
Net income
1 |
-70.32
|
-167.1
|
-214
|
-123.3
|
-156.1
|
-178.6
|
-149.3
|
Net margin
|
-
|
-
|
-
|
-5,037.88%
|
-6,901.33%
|
-18,084.58%
|
-180.32%
|
EPS
2 |
-27.60
|
-59.10
|
-69.60
|
-18.69
|
-10.05
|
-9.990
|
-7.470
|
Free Cash Flow
1 |
-52.62
|
-125.6
|
-
|
-111.2
|
-110.4
|
-148.5
|
-82
|
FCF margin
|
-
|
-
|
-
|
-4,543.77%
|
-4,881.04%
|
-15,036.26%
|
-99.04%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/21
|
2/28/22
|
2/7/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
0.683
|
0.781
|
0.468
|
0.515
|
0.431
|
1.172
|
0.3385
|
0.3385
|
0.2952
|
0.2952
|
EBITDA
1 |
-58.56
|
-68.76
|
-60.28
|
-44.19
|
-41.35
|
-37.98
|
-34.85
|
-25.41
|
-27.7
|
-
|
-42.41
|
-43.46
|
-44.52
|
-
|
-
|
EBIT
1 |
-58.66
|
-68.85
|
-60.39
|
-44.29
|
-41.45
|
-38.09
|
-34.96
|
-25.52
|
-27.81
|
-41.89
|
-38.58
|
-39.77
|
-40.09
|
-40.25
|
-40.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-5,577.01%
|
-4,476.31%
|
-5,452.14%
|
-5,399.22%
|
-9,718.33%
|
-3,292.35%
|
-11,747.59%
|
-11,843.6%
|
-13,633.98%
|
-13,751.62%
|
Earnings before Tax (EBT)
1 |
-58.59
|
-68.72
|
-60.19
|
-43.94
|
-41.17
|
-37.46
|
-34.31
|
-24.63
|
-26.88
|
-39.55
|
-37.53
|
-38.77
|
-39.13
|
-39.6
|
-43.06
|
Net income
1 |
-58.58
|
-68.72
|
-60.19
|
-43.94
|
-41.17
|
-37.46
|
-34.31
|
-24.63
|
-26.88
|
-39.55
|
-37.53
|
-38.77
|
-39.13
|
-39.6
|
-43.06
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-5,483.89%
|
-4,393.34%
|
-5,263.25%
|
-5,219.03%
|
-9,177.03%
|
-3,202.29%
|
-11,453%
|
-11,560.24%
|
-13,411.01%
|
-14,585.94%
|
EPS
2 |
-19.50
|
-22.65
|
-19.80
|
-14.40
|
-13.05
|
-10.65
|
-7.350
|
-2.700
|
-2.970
|
-2.840
|
-2.250
|
-2.320
|
-2.322
|
-2.198
|
-2.365
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/9/22
|
8/8/22
|
11/9/22
|
2/7/23
|
5/11/23
|
8/9/23
|
11/7/23
|
3/5/24
|
5/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
81.3
|
406
|
313
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-52.6
|
-126
|
-
|
-111
|
-110
|
-148
|
-82
|
ROE (net income / shareholders' equity)
|
-
|
-62.1%
|
-131%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
7.920
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-44.00
|
-60.20
|
-
|
-
|
-
|
-
|
Capex
|
-
|
1.05
|
-
|
0.05
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
2.04%
|
-
|
-
|
-
|
Announcement Date
|
3/17/21
|
2/28/22
|
2/7/23
|
3/5/24
|
-
|
-
|
-
|
Last Close Price
47.46
USD Average target price
137.2
USD Spread / Average Target +189.02% Consensus |
1st Jan change
|
Capi.
|
---|
| +113.02% | 812M | | +43.36% | 54.63B | | -5.31% | 39.92B | | +14.75% | 26.86B | | -12.56% | 26.22B | | -22.45% | 18.78B | | +25.12% | 12.21B | | +0.04% | 12.16B | | +26.04% | 11.94B | | -11.83% | 10.74B |
Other Biotechnology & Medical Research
|